The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients

被引:118
作者
Lobaton, Triana [1 ]
Bessissow, Talat [2 ]
De Hertogh, Gert [3 ]
Lemmens, Bart [3 ]
Maedler, Chelsea [4 ]
Van Assche, Gert [1 ]
Vermeire, Severine [1 ]
Bisschops, Raf [1 ]
Rutgeerts, Paul [1 ]
Bitton, Alain [2 ]
Afif, Waqqas [2 ]
Marcus, Victoria [4 ]
Ferrante, Marc [1 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol, B-3000 Louvain, Belgium
[2] Royal Victoria Hosp, Dept Gastroenterol, Montreal, PQ H3A 1A1, Canada
[3] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pathol, B-3000 Louvain, Belgium
[4] Royal Victoria Hosp, Dept Pathol, Montreal, PQ H3A 1A1, Canada
关键词
Endoscopic scores; ulcerative colitis; disease extent; TERM-FOLLOW-UP; DOUBLE-BLIND; FECAL CALPROTECTIN; COMBINATION THERAPY; DISEASE-ACTIVITY; NATURAL-HISTORY; OPEN-LABEL; VALIDATION; INFLIXIMAB; PROCTOSIGMOIDITIS;
D O I
10.1093/ecco-jcc/jjv111
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Current endoscopic activity scores for ulcerative colitis (UC) do not take into account the extent of mucosal inflammation. We have developed a simple endoscopic index for UC that takes into account the severity and distribution of mucosal inflammation. Methods: In this multicentre trial, UC patients undergoing colonoscopy were prospectively enrolled. For the Modified Score (MS), the sum of Mayo Endoscopic Subscores (MESs) for five colon segments (ascending, transverse, descending, sigmoid and rectum) was calculated. The Extended Modified Score (EMS) was obtained by multiplying the MS by the maximal extent of inflammation. The Modified Mayo Endoscopic Score (MMES) was obtained by dividing the EMS by the number of segments with active inflammation. Colon biopsies were obtained from the rectum and sigmoid, as well as from all inflamed segments, by standard methods. Clinical activity was scored according to the Partial Mayo Score (PMS). Biological activity was scored according to C-reactive protein (CRP) and faecal calprotectin (FC) levels. Histological activity was scored according to the Geboes Score (GS). Results: One hundred and seventy-one UC patients (38% female, median age 47 years, median disease duration 13 years) were included. The MMES correlated significantly with the PMS (r = 0.535), CRP (r = 0.238), FC (r = 0.730) and GS (r = 0.615) (all p < 0.001). Median MMES scores were significantly higher in patients with clinical, biological or histological activity (all p = 0.001) Conclusions: The MMES is an easy to use endoscopic index for UC that combines the severity analysis of the MES with disease extent, and correlates very well with clinical, biological and histological disease activity.
引用
收藏
页码:846 / 852
页数:7
相关论文
共 43 条
  • [31] Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission
    Paoluzi, OA
    Pica, R
    Marcheggiano, A
    Crispino, P
    Iacopini, F
    Iannoni, C
    Rivera, M
    Paoluzi, P
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) : 1751 - 1759
  • [32] COMPARISON OF ORAL PREDNISOLONE GIVEN AS SINGLE OR MULTIPLE DAILY DOSES FOR ACTIVE PROCTOCOLITIS
    POWELLTUCK, J
    BOWN, RL
    LENNARDJONES, JE
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1978, 13 (07) : 833 - 837
  • [33] COATED MESALAZINE (5-AMINOSALICYLIC ACID) VERSUS SULPHASALAZINE IN THE TREATMENT OF ACTIVE ULCERATIVE-COLITIS - A RANDOMIZED TRIAL
    RACHMILEWITZ, D
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1989, 298 (6666): : 82 - 86
  • [34] 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants
    Reinisch, Walter
    Sandborn, William J.
    Panaccione, Remo
    Huang, Bidan
    Pollack, Paul F.
    Lazar, Andreas
    Thakkar, Roopal B.
    [J]. INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1700 - 1709
  • [35] Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study
    Rizzello, F
    Gionchetti, P
    D'Arienzo, A
    Manguso, F
    Di Matteo, G
    Annese, V
    Valpiani, D
    Casetti, T
    Adamo, S
    Prada, A
    Castiglione, GN
    Varoli, G
    Campieri, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (06) : 1109 - 1116
  • [36] Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein
    Roseth, AG
    Aadland, E
    Jahnsen, J
    Raknerud, N
    [J]. DIGESTION, 1997, 58 (02) : 176 - 180
  • [37] Infliximab for induction and maintenance therapy for ulcerative colitis
    Rutgeerts, P
    Sandborn, WJ
    Feagan, BG
    Reinisch, W
    Olson, A
    Johanns, J
    Travers, S
    Rachmilewitz, D
    Hanauer, SB
    Lichtenstein, GR
    de Villiers, WJS
    Present, D
    Sands, BE
    Colombel, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) : 2462 - 2476
  • [38] Validation of the Ulcerative Colitis Colonoscopic Index of Severity and Its Correlation With Disease Activity Measures
    Samuel, Sunil
    Bruining, David H.
    Loftus, Edward V., Jr.
    Thia, Kelvin T.
    Schroeder, Kenneth W.
    Tremaine, William J.
    Faubion, William A.
    Kane, Sunanda V.
    Pardi, Darrell S.
    de Groen, Piet C.
    Harmsen, William S.
    Zinsmeister, Alan R.
    Sandborn, William J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (01) : 49 - U178
  • [39] Sandborn WJ, 2009, GASTROENTEROLOGY, V137, P1250, DOI 10.1053/j.gastro.2009.06.061
  • [40] Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Feagan, Brian G.
    Marano, Colleen
    Zhang, Hongyan
    Strauss, Richard
    Johanns, Jewel
    Adedokun, Omoniyi J.
    Guzzo, Cynthia
    Colombel, Jean-Frederic
    Reinisch, Walter
    Gibson, Peter R.
    Collins, Judith
    Jarnerot, Gunnar
    Hibi, Toshifumi
    Rutgeerts, Paul
    [J]. GASTROENTEROLOGY, 2014, 146 (01) : 85 - 95